Legend Biotech (LEGN) Reports $1.9B Sales for CARVYKTI in 2025

Legend Biotech Corporation (LEGN) announced financial results for 2025, achieving $1.9 billion in net trade sales from its CARVYKTI therapy, including ~$555 million in Q4. The company reported a collaboration revenue increase to $277.6 million in the final quarter. With over 10,000 patients treated and a global footprint expanding to 294 sites across 14 markets, LEGN is positioned for growth. Additionally, the company opened a new 31,000-square-foot R&D facility in Philadelphia to support its pipeline advancements.